^
Association details:
| Biomarker: | EZH2 underexpression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic value of EZH2 expression for immunotherapy-based schemes in advanced soft-tissue sarcoma: A translational research from Spanish Group of Research on Sarcoma (GEIS).
Published date:
05/26/2022
Excerpt:
...low expression of EZH2 was also significantly associated with a clinical benefit of the patients treated with nivolumab plus sunitinib [relative risk (RR): 13; 95% CI: 3.0-56.9; p = < 0.001)….Low expression of EZH2 was associated with better outcome in advanced STS patients treated with immunotherapy-based schemes.
DOI:
10.1200/JCO.2022.40.16_suppl.11549
